- Home
- SNT vs GNLX Comparison
SNT vs GNLX Comparison
Compare SNT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- GNLX
- Stock Information
- Founded
- SNT 1965
- GNLX 2001
- Country
- SNT Canada
- GNLX United States
- Employees
- SNT N/A
- GNLX N/A
- Industry
- SNT Telecommunications Equipment
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- GNLX Health Care
- Exchange
- SNT Nasdaq
- GNLX Nasdaq
- Market Cap
- SNT 95.2M
- GNLX 96.6M
- IPO Year
- SNT 1993
- GNLX 2023
- Fundamental
- Price
- SNT $3.96
- GNLX $3.06
- Analyst Decision
- SNT
- GNLX Strong Buy
- Analyst Count
- SNT 0
- GNLX 4
- Target Price
- SNT N/A
- GNLX $17.75
- AVG Volume (30 Days)
- SNT 80.6K
- GNLX 129.5K
- Earning Date
- SNT 05-27-2025
- GNLX 05-06-2025
- Dividend Yield
- SNT N/A
- GNLX N/A
- EPS Growth
- SNT N/A
- GNLX N/A
- EPS
- SNT 0.18
- GNLX N/A
- Revenue
- SNT $36,690,000.00
- GNLX N/A
- Revenue This Year
- SNT N/A
- GNLX N/A
- Revenue Next Year
- SNT N/A
- GNLX N/A
- P/E Ratio
- SNT $22.00
- GNLX N/A
- Revenue Growth
- SNT 8.36
- GNLX N/A
- 52 Week Low
- SNT $1.34
- GNLX $1.60
- 52 Week High
- SNT $4.29
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- SNT 58.27
- GNLX 64.52
- Support Level
- SNT $3.65
- GNLX $2.53
- Resistance Level
- SNT $3.95
- GNLX $2.84
- Average True Range (ATR)
- SNT 0.25
- GNLX 0.21
- MACD
- SNT -0.02
- GNLX 0.06
- Stochastic Oscillator
- SNT 48.44
- GNLX 81.93
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.